AllDocs -> cancers

Bladder Cancer Beth Ruyak/Host “For people suffering from bladder cancer , the standard approach has been to remove the bladder , which meant the patient had to wear a bag to collect urine. This method served many people well but seriously affected their quality of life. Now, new and less intrusive treatment options without the bag have become available.” RICHARD MANNING SPENDS MOST OF HIS DAYS IN HIS GARAGE WOODWORKING. IT’S A HOBBY THAT HAS BECOME THIS RETIRED PRINTER’S SECOND CAREER. BUT THERE WAS A TIME WHEN A SECOND CAREER WAS NOT FORESEEABLE IN RICHARD’S FUTURE. Richard Manning/ Bladder Cancer Survivor “I was passing stones. I had lower back pains and pains in my hip area, and they said I had rheumatism.” “THEY” WERE THE MANY DOCTORS RICHARD VISITED TRYING TO DISCOVER WHAT WAS WRONG WITH HIM. FINALLY, ONE DOCTOR TOOK AN X-RAY AND FOUND OUT. Manning “And it was a shock ...

Mac Overmyer UT CONTRIBUTING EDITOR Houston— Nuclear matrix protein 22 (NMP22) is to bladder cancer as PSA is to prostate cancer , perhaps better. That is the implication of a recently published, pro- spective, multi-institution study showing the point-of- care NMP22 assay (BladderChek, Matritech, Newton, MA) has a sensitivity of 55.7% and a specificity of 85.7%. In contrast, cytology was found to have lower sensitivity (15.8%) but higher specificity (99.2%). When used in conjunction with cystoscopy, the office- based test detected 94% of bladder cancers, compared with 89% detected by cys- toscopy alone, the authors reported. It also identified four invasive, life-threatening cancers missed during cystoscopy. The study appears in the Feb. 16 issue of JAMA (2005; 293:810-6). Lead author H. Barton ...

30 Synthesis and application of isotopically labeled compounds 2001 , 7(2) : 399-402 Preparation of anti- bladder cancer monoclonal antibody BDI-1 labeled with rhenium-188 Rongfu Wang, Chungli Zhang, Lizhang Yu, Yifeng Guo, Ying Bai (Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, P. R. China) Summary The anti-human bladder cancer monoclonal antibody BDI-1 was radiolabeled with rhenium-188 by direct labeling methods using SnCl 2 as reductant and MDP as stannous stabilizer or by indirect method using NHS-ECM ester as bifunctional chelator. Radiochemical yields of 30% ± 7.23% and 87.4% ± 5.76% and radiochemical purity of more than 95% were achieved. Inmmunoreactive fraction was 58.7%. The results showed that radionuclide 188 Re might be employed methodology for using the same labeling ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN BLADDER CANCER TISSUE MICROARRAY Catalog Number: TMA-002 Each core from each tissue represents one specimen selected and pathologically confirmed. Normal matched or unmatched bladder tissue is provided for comparison to the cancer tissue. Cases : 53 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Cytokeratin confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 ...

Special Communication The International Bladder Cancer Bank: proposal for a new study concept Peter J. Goebell a,b, *, Susan Groshen c , Bernd J. Schmitz-Dräger d , Richard Sylvester e , Manolis Kogevinas f , Núria Malats f , Guido Sauter g , H. Barton Grossman h , Fred Waldman i , Richard J. Cote a a Departments of Pathology and Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA b Department of Urology, University of Essen, Essen, Germany c Department of Preventive Medicine, USC/Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA d ...

Trends in Cancer Mortality by Health Zone in Queensland Bladder cancer Rate per 100,000 population Mortality of Bladder cancer , by Health Zone, Queensland, 1986 to 2002 Northern Central Southern 0 3 6 9 12 15 Year 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Note: Rates are age standardised to the Australian population as at 30 June 2001. Data are reported by place of usual residence and year of diagnosis. Bladder cancer is defined by the ICD-0-2 codes of C67 Source: Queensland Cancer Registry, Queensland Health and Queensland Cancer Fund. Generated by Epidemiology Services Unit, Queensland Health For more information: Health Status Indicators for Queensland Queensland ...

Cancer Mortality by Remoteness Category in Queensland Bladder cancer 0 3 6 9 12 15 18 0 3 6 9 12 15 18 Male Female Rate per 100,000 population Rate per 100,000 population Avg No. Avg No. per Year per Year Mortality of Bladder cancer , by ARIA+ Category and Sex, Queensland, Five Year Average, 1998 to 2002 8.4 59 2.4 25 Major City ARIAplus Category 7.9 34 2.1 11 Inner Regional 7.6 16 2.1 6 Outer Regional 7.7 1 0.0 0 Remote 7.3 1 4.4 1 Very remote Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers and rates are averaged over five ...

Bladder Cancer The National Cancer Institute ( http://www. cancer .gov/ ), lists bladder cancer as one of 13 common causes of cancer and provides the following information. To obtain a free copy of this document, go to www.masterdocs.com . Understanding Cancer Cancer begins in cells, the building blocks that make up tissues . Tissues make up the organs of the body. Normally, cells grow and divide to form new cells as the body needs them. When cells grow old, they die, and new cells take their place. Sometimes this orderly process goes wrong. New cells form when the body does not need them, and old cells do not die when they should. These extra cells can form a mass of tissue called a growth or tumor . Not all tumors are cancer . Tumors can be benign or malignant : Benign tumors are not cancer : • Benign tumors are rarely life-threatening. ...

21 Urinary Bladder Cancer Cancer of the urinary bladder is the fifth most common cancer in the United States. Each year, approximately 38,000 men and 15,000 women are diagnosed with bladder cancer . This is the fourth most common type of cancer in men and the eighth most common in women. Like almost any malignancy, bladder cancer is a multifactorial disease with both an environmental and genetic component. The most important known risk factor for bladder cancer is cigarette smoking; cigarette smokers develop bladder cancer two to three times more often than nonsmokers (Silverman et al., in press). Risk increases with amount smoked (number of packs per day), with moderate to heavy smokers experiencing two to five times the risk of nonsmokers. Quitting smoking is associated with a 30% to 60% decrease in risk. Smoking is estimated to be responsible for about 48% of the bladder ...

Amicus – Printing, bladder cancer and C23 benefit Page 1 of 6 PRINTING, BLADDER CANCER AND C23 BENEFIT INTRODUCTION Bladder Cancer is described as Prescribed Disease C23, and as such is one that has been officially accepted as a special risk of certain specified occupations, or of exposure to specified substances. Most occupational Bladder Cancers have been linked to work in the manufacture of dyestuffs, in the rubber and cable industries and in the retort houses of gasworks producing coal gas. However, it is widely accepted that the incidence of Bladder Cancer may be raised in certain other industries, including the printing industry. This has been recognised by many articles on Bladder Cancer , but in particular by the Industrial Injuries Advisory Council in their 1983 report on Neoplasm of the Bladder , where they stated that: "There is some evidence that certain ...

Prescribed diseases - Bladder Cancer Introduction The law provides for payment of benefits to people who are suffering from certain diseases contracted in the course of certain types of employment. These diseases are referred to as prescribed diseases (PDs) and are listed in Regulations. A disease or injury is prescribed when the Secretary of State is satisfied that it is a risk arising from a person’s occupation and not a risk common to everybody. Bladder cancer is recognized as such a disease. If you are told that you are not entitled to benefit for a certain disease, it does not mean you do not have the disease for which you claimed. What you are being told is that you do not meet the criteria laid down for receiving benefit for that disease. These criteria are laid down so that it can be presumed that your job caused the prescribed disease in question. This is especially important ...

November/December 2004, Vol. 11, No. 6 358 Cancer Control Bladder Preservation Clinical Trials of the Radiation Therapy Oncology Group Over the last 3 decades, the Radiation Therapy Oncology Group (RTOG) has conducted six prospective clinical tri- als in patients with muscle-invasive bladder cancer (Table 1) who were otherwise candidates for cystectomy. 1 The basic approach is similar in all six trials: patients received an initial maximal transurethral resection of the bladder tumor (TURBT),followed by radiation therapy to the blad- der with concurrent cisplatin-containing chemotherapy. Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer Javier F. Torres-Roca, MD Background: Over the last 3 decades, we have seen a paradigm shift in our approach to the treatment of malignancy. During that ...

Disease profiling in superficial bladder cancer Dr. E. Solsona Chief of Service of Urology. Instituto Valenciano de Oncología. Valencia. Spain. Superficial bladder tumours are a heterogeneous tumour family characterised by its capacity to develop superficial recurrence and, in less extent, progression to muscle-invasive tumours. As a whole, from 37.2 to 72.7% of patients will develop superficial recurrence and from 2.2 to 49% progressions (table 1). Transurethral resection is the standard treatment for these patients, but according to previous data is insufficient in a vast majority of them. Since seventies intravesical adjuvant therapies have been applied in order to reduce recurrence and to prevent or at least delay progression. Some drugs have been used as intravesical chemotherapy and, more recently, intravesical immunotherapy, essentially based on bacillus Calmette-Guerin. In randomised ...

CIGARETTE SMOKING AND BLADDER CANCER IN MEN: A POOLED ANALYSIS OF 11 CASE-CONTROL STUDIES Paul B RENNAN 1 *, Olivier B OGILLOT 1 , Sylvaine C ORDIER 2 , Eberhard G REISER 3 , Walter S CHILL 3 , Paolo V INEIS 4 , Gonzalo L OPEZ -A BENTE 5 , Anastasia T ZONOU 6 , Jenny C HANG -C LAUDE 7 , Ulrich B OLM -A UDORFF 8 , Karl-Heinz J OCKEL 9 , Francesco D ONATO 10 , Consol S ERRA 11 , Jorgen W AHRENDORF 7 , Martine H OURS 12 , Andrea T’M ANNETJE 1 , Manolis K OGEVINAS ...

Abstract. Chromosomal aneuploidy is associated with invasive bladder cancer and one of the genes implicated in these changes is Aurora-A/STK15/BTAK, that is localized on chromosome 20q13 and encodes a centrosome-associated serine/threonine kinase. To better understand the association between Aurora-A/STK15 expression, tumor aneuploidy and clinical prognosis, we sought to determine whether overexpression of Aurora-A/STK15 in cultured urothelial cells facilitated chromosomal instability. Using immuno- fluorescence staining, Northern and Western blot analyses, we verified that overexpression of Aurora-A/STK15 in bladder tumor cell lines enhanced chromosomal instability. Additionally, we observed that some bladder tumor cell lines expressed more Aurora-A/STK15 than cultured normal urothelial cells and that Aurora-A/STK15 expression was higher in an immortalized E7 urothelial cell line having 20q ...

How does your dog smell? Olfactory detection of human bladder cancer Leanne Tite takes you through a proof of principle study about whether dogs can detect bladder cancer through the smell of human urine This month’s paper is Willis CM, Church SM, Guest CM, Cook WA, McCarthy, N, Bransbury AJ, et al. Olfactory detection of human bladder cancer by dogs: proof of prin- ciple study. BMJ 2004;329:712. You can read it by visiting studentbmj.com and clicking on the link. Why do the study? Anecdotal evidence has shown that dogs, with their acute sense of smell, might be able to detect cancers in humans by picking up the odour given off by the cancer cells. In the past 15 years, two letters have been published in the Lancet , seemingly describing dogs’ ability to predict the presence of cancer later diagnosed by a doctor. Alongside the anecdotes, good theoretical ...

European Science Foundation Standing Committee for the European Medical Research Councils (EMRC) ESF EMRC EXPLORATORY WORKSHOP Drinking Water Chlorination and Bladder Cancer Athens, Greece, 2-4 November 2004 Convened by: Peter J. Goebell University Clinic of Essen Page 2 The European Science Foundation (ESF) acts as a catalyst for the development of science by bringing together leading scientists and funding agencies to debate, plan and implement pan-European scientific and science policy initiatives. ESF is the European association of 76 major national funding agencies devoted to scientific research in 29 countries. It represents all scientific disciplines: physical and engineering sciences, life and environmental sciences, medical sciences, humanities and social sciences. The Foundation assists its Member Organisations ...

192 LAPAROSCOPIC PARTIAL CYSTECTOMY Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology Vol. 30 (3): 192-198, May - June, 2004 LAPAROSCOPIC PARTIAL CYSTECTOMY IN BLADDER CANCER – INITIAL EXPERIENCE MIRANDOLINO B. MARIANO, MARCOS V. TEFILLI Section of Urology, Hospital Mãe de Deus, Porto Alegre, Rio Grande do Sul, Brazil ABSTRACT Proposal: The authors present their initial experience with a selected group of patients who underwent laparoscopic partial cystectomy for treating bladder cancer . Materials and Methods: In the period from June 1997 to April 2000, 6 patients, aged be- tween 38 and 76 years, having transitional cell carcinoma of the bladder , were identified as candidates to partial cystectomy.The procedure employed consisted in laparoscopic partial cystectomy and lym- phadenectomy with exclusive intracorporeal ...

bladder cancer 1581 Toenail arsenic and bladder cancer : findings from a cohort study of male smokers Dominique S. Michaud Assistant Professor Department of Epidemiology Harvard School of Public Health, Boston Outline Arsenic and bladder cancer High dose studies Low dose studies Arsenic measurements in toenails Methods: ATBC study Results Discussion Future directions High arsenic levels and bladder cancer Ecological studies have consistently reported elevated mortality rates of bladder cancer in arsenic endemic areas: Taiwan Argentina northern Chile High arsenic levels and bladder cancer Elevated bladder cancer incidence and ...

Arsenic in Drinking Water and Bladder Cancer Mortality in the United States: An Analysis Based on 133 U.S. Counties and 30 Years of Observation Steven H. Lamm, MD Arnold Engel, MD Michael B. Kruse, PhD Manning Feinleib, MD Daniel M. Byrd, PhD Shenghan Lai, PhD Richard Wilson, DPhil This study analyzes the relationship between arsenic exposure through drinking water and bladder cancer mortality. The county-specific white male bladder cancer mortality data (1950–1979) and county-specific groundwater arsenic concentration data were obtained for 133 U.S. counties known to be exclusively dependent on groundwater for their public drinking water supply. No arsenic-related increase in bladder cancer mortality was found over the exposure range of 3 to 60 g/L using stratified analysis and regression analyses (both unweighted and weighted ...

MARCH 2004 European Association of Urology GUIDELINES ON BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC G. Jakse, F. Algaba, S. Fossa, A. Stenzl, C. Sternberg Page 2 TABLE OF CONTENTS PAGE 1 INTRODUCTION 4 2 CLASSIFICATION 4 2.1 TNM staging 4 2.2 Histological grading 4 2.3 References 5 3 RISK FACTORS 5 4 DIAGNOSIS 5 4.1 Symptoms 5 4.2 Physical examination 5 4.3 Cystoscopy and TUR 5 4.4 References 5 5 STAGING 6 5.1 T-staging 6 5.1.1 TUR and bimanual palpation 6 5.1.2 Imaging 6 5.1.2.1 Intravenous pyelography 6 5.1.2.2 Ultrasonography 6 5.1.2.3 Computed tomography 6 5.1.2.4 Magnetic resonance ...

© The Ulster Medical Society, 2002. 128 The Ulster Medical Journal The Ulster Medical Journal, Volume 71, No. 2, pp. 128-131, November 2002. Case Report Gall bladder cancer – Radical surgery, the key role to improve outcome P Bhuta, M G Brown, J M Alderdice Accepted 12 June 2002 Causeway Hospital, Coleraine, Co. Londonderry. P Bhuta, FRCS, Surgical Registar M G Brown, MD, FRCS, Consultant Surgeon Dr J M Alderdice, FRCPath, Consultant Pathologist Correspondence to Mr Bhuta Gall bladder cancer is one of five most common malignancies of the gastro-intestinal tract. Most of the cancers are detected during histological examination after cholecystectomy. Females are more commonly affected than males with a ratio of 4:1. A direct association exists between the presence of cholelithiasis and the development of gall bladder carcinoma. In patients ...

Tumori, 90: 175-180, 2004 Acknowledgments : Funded by the Ministry for Science and Technology of Serbia through contract No. 1460. Correspondence to : Dr Vladan Radosavljevic, Institute of Preventive Medicine, Sonje Marinkovic4, 11080 Zemun-Belgrade, Serbia. Tel +381-064-2371485; fax +381-11-625871; e-mail rvladan@eunet.yu Received March 27, 2003; accepted August 28, 2003. NON-OCCUPATIONAL RISK FACTORS FOR BLADDER CANCER A CASE-CONTROL STUDY Vladan Radosavljevic 1 , Slavenka Jankovic 2 , Jelena Marinkovic 3 , and Milan -Dokic 4 1 Institute of Preventive Medicine, Zemun-Belgrade; 2 Institute of Epidemiology, School of Medicine, Belgrade University; 3 Institute for Statistics and Informatics, School of Medicine, Belgrade University; 4 Institute of Nephrology ...

BLADDER CANCER IN MARIN COUNTY, 1995-1999 0 10 20 30 40 50 60 Marin SF Bay Area Urban CA Incidence Mortality * In general, bladder cancer is far more common among men than among women, and more common among white non-Hispanic men than among men of other ethnicities. The small size of the African- American, Hispanic, and Asian populations in Marin County prevents the calculation of stable incidence rates for these populations. For this reason, and because the incidence of bladder cancer varies by race/ethnicity, the above data includes only white non-Hispanic Marin County residents. Age-adjusted rates of invasive and in situ bladder cancer among individuals of white-non-Hispanic race/ethnicity, 1995-1999: Incidence Rates: Males Females Marin: 45.0/100,000 14.5/100,000 San ...

Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity MAL Moneef 1 , BT Sherwood 1,2 , KJ Bowman 1 , RC Kockelbergh 2 , RP Symonds 3 , WP Steward 3 , JK Mellon 2 and GDD Jones * ,1 1 Department of Cancer Studies and Molecular Medicine, Hodgkin Building, University of Leicester, Lancaster Road, PO Box 138, Leicester LE1 9HN, UK; 2 University Division of Urology, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK; 3 University Department of Cancer Studies and Molecular Medicine, Osborne Building, Leicester Royal Infirmary, Leicester LE1 5WW, UK In the UK, the two main treatments of invasive bladder cancer are radiotherapy or cystectomy. However, B50% of patients ...

Eur Urol 1992;21(suppl 2):1 J.-A. Martínez-Piñeiro BCG for Superficial Bladder Faculty of Medicine, Universidad Autónoma, Madrid, Spain Cancer An Introduction Bacillus Calmette-Guérin (BCG) non-specific immu- notherapy for superficial bladder cancer may be regarded as the most successful of all immunotherapies in man. Since its introduction into superficial bladder cancer by Morales [1] and by Martinez-Pifieiro [2] in 1976, the impact of BCG in the management of superficial bladder neoplasms, in particular carcinoma in situ (CIS), has been so remarkable that it is currently considered to be the greatest step ever taken towards the control of these malignancies. Three distinct clinical applications for BCG have emerged in the 15 years which have elapsed since the initial reports in 1976. Firstly, prophylaxis of recurrence, ...

Eur Urol 1992;21(suppl 2):7-11 F. Pagano P. Bassi C. Milani N. Piazza A. Meneghini A.Garbeglio BCG in Superficial Bladder Cancer : A Review of Phase III European Trials Istituto di Urologia, Universith degli Studi, Monoblocco Ospedaliero, Padova, Italy . Key Words Abstract BCG Shortly after Morales’ original report, several phase II trials confirmed the effec- Superficial bladder cancer tiveness of intravesical bacillus Calmette-Guérin (BCG) in superficial bladder Phase III trials cancer therapy. Concerns have been expressed about the toxicity related to this Review new therapeutic modality. These phase II trial data led European urologists to try to answer some questions related to BCG therapy, such as the optimal schedule and dose, the most effective BCG strain and the value of ...

Eur Urol 1995;27(suppl 1):2-8 D.L. Lamm BCG in Perspective: West Virginia University, Morgantown, W. Va., USA .. . .. .. Key Words Superficial bladder cancer BCG Immunotherapy Intravesical therapy Advances in the Treatment of Superficial Bladder Cancer Abstract The management of superficial bladder cancer has advanced significantly in recent years. Controlled clinical trials suggest the benefits of cytotoxic chemo- therapy apply primarily to well-differentiated tumours, are short-term and do not include a reduction in disease progression. In contrast, intravesical bacil- lus Calmette-Guérin (BCG) immunotherapy is effective in high-grade tu- mours, provides long-term protection from tumour recurrence and reduces disease progression. Controlled clinical trials have consistently demonstrated that BCG provides ...